Using this framework and pretreatment RNA-Seq or NanoString tumor expression profiling, they have identified that TIDE more accurately predicts the outcome of melanoma patients treated with first-line anti-PD-1 or anti-CTLA-4 than other biomarkers such as PD-L1 levels and TMB. The gene discussed is CTLA4; the disease is neoplasm.